@article{oai:kanazawa-u.repo.nii.ac.jp:00013567,
 author = {Yokoyama, Hitoshi and Wada, Takashi and Zhang, Wei and Yamaya, Hideki and Asaka, Mitsuhiro},
 issue = {2},
 journal = {Clinical and Experimental Nephrology},
 month = {Jun},
 note = {This article is an overview of the immunomodulatory effects of apheresis in renal diseases, especially primary and secondary glomerulonephritis, and the clinical evidence for the efficacy of apheresis therapy. Permeability factor(s) derived from circulating T cells are speculated to have a crucial role in the proteinuria of nephrotic syndrome (NS). Plasma exchange (PE); immunoadsorption plasmapheresis (IAPP), using protein A sepharose cartridges; low-density lipoprotein apheresis; and lymphocytapheresis (LCAP) have been used to remove such factors or pathogenic T cells. Other glomerular diseases induced by specific antibodies such as anti-glomerular basement membrane antibodies, anti-neutrophil cytoplasmic antibodies, and immune-complexes have also been treated with PE, double-filtration plasmapheresis, IAPP, and LCAP. Recommendations, based on the evidence from recent randomized controlled studies, have been established in apheresis therapy for various glomerular diseases. © 2007 Japanese Society of Nephrology.},
 pages = {122--127},
 title = {Advances in apheresis therapy for glomerular diseases},
 volume = {11},
 year = {2007}
}